Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma

The most common adverse events associated with tislelizumab and/or chemotherapy drugs were anemia (n = 18), followed by decreased appetite (n = 17), nausea (n = 16), and asthenia (n = 15). [...]the objective response rates and disease control rates for both ESCC and G/GEJ adenocarcinoma were 46.7% a...

Full description

Saved in:
Bibliographic Details
Published inThoracic cancer Vol. 11; no. 12; pp. 3419 - 3421
Main Author Qiu, Hai‐Bo
Format Journal Article
LanguageEnglish
Published Melbourne John Wiley & Sons Australia, Ltd 01.12.2020
John Wiley & Sons, Inc
Subjects
Cancer therapies
Chemotherapy
Clinical trials
Esophageal cancer
Medical prognosis
Medical research
Metastasis
Monoclonal antibodies
Patients
Squamous cell carcinoma
Targeted cancer therapy
China
Online AccessGet full text

Cover

More Information
Summary:The most common adverse events associated with tislelizumab and/or chemotherapy drugs were anemia (n = 18), followed by decreased appetite (n = 17), nausea (n = 16), and asthenia (n = 15). [...]the objective response rates and disease control rates for both ESCC and G/GEJ adenocarcinoma were 46.7% and 80.0%, respectively. The reported adverse events related to the combination therapy were consistent with the known adverse events associated with chemotherapy alone. [...]no adverse events related to tislelizumab alone were observed in this study. [...]the sample size of this study was too small (15 ESCC and 15 G/GEJ adenocarcinoma patients) and no new safety signals were reported, therefore, the conclusions on safety and the data of survival are limited.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1759-7706
1759-7714
DOI:10.1111/1759-7714.13690